Search
Econazole
go.drugbank.com/drugs/DB01127ApprovedA broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.
Mixtures: PM ExternalCategories: Antifungals for Topical Use, Antifungals for Dermatological UseButenafine
go.drugbank.com/drugs/DB01091ApprovedIn particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes.
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseSynonyms: N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamineValdecoxib
go.drugbank.com/drugs/DB00580ApprovedWithdrawnValdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTrilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigationalG1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for … [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016.
Categories: Detoxifying Agents for Antineoplastic Treatment, P-glycoprotein substratesHSD-016
go.drugbank.com/drugs/DB12419InvestigationalHsd 016 is under investigation in clinical trial NCT00838461 (Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016).
Deutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalThe most prominent physical symptom of HD that may increase the risk of injury is chorea, which is an involuntary, sudden movement that can affect any muscle and flow randomly across body regions [A32046 … Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine [A32042].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesZinc dibutyldithiocarbamate
go.drugbank.com/drugs/DB14194ApprovedSensitivity to zinc dibutyldithiocarbamate may be identified with a clinical patch test.
Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical UseVoclosporin
go.drugbank.com/drugs/DB11693ApprovedInvestigational[L31253] In July 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended voclosporin be granted marketing authorization for use in combination with [mycophenolate mofetil] … [L31208] Voclosporin has demonstrated a more stable pharmacokinetic and pharmacodynamic relationship than cyclosporine, a higher potency than cyclosporine, and an improved metabolic profile when compared
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesYohimbine
go.drugbank.com/drugs/DB01392ApprovedInvestigationalVet approvedWithdrawnIt is also alleged to be an aphrodisiac.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsApomorphine
go.drugbank.com/drugs/DB00714ApprovedInvestigational[A203618] Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates